Budesonide Formoterol Inhaler CFC Free 200doses Aerosolized
Product : Budesonide Aerosol CFC-free
Specification : 200mcg/Dose, 200doses
Standard : BP, USP
Packing : one bottle/box
Budesonide is a white or almost white, crystalline powder that is
practically insoluble in water, sparingly soluble in ethanol, and
freely soluble in methylene chloride.Budesonide inhalation
suspension is a sterile suspension for inhalation via jet nebulizer
and contains the active ingredient budesonide (micronized)
Indication and Usage :
The product is indicated for the maintenance treatment of asthma as
prophylactic therapy in patients six years of age or older.
After priming, each actuation of the inhaler delivers 200mcg of
Budesonide inhalation suspension is NOT indicated for the relief of
Budesonide has a high glucocorticoid effect and a weak
mineralocorticoid effect. It binds to the glucocorticoid receptor
with a higher binding affinity than cortisol and prednisolone. When
budesonide is systemically administered, suppression of endogenous
cortisol concentrations and an impairment of the
hypothalamus-pituitary-adrenal (HPA) axis function has been
observed. Furthermore, a decrease in airway reactivity to histamine
and other entities has been observed with the inhaled formulation.
Generally, the inhaled formulation has a rapid onset action and
improvement in asthma control can occur within 24 hours of
initiation of treatment.
Mechanism of action
Budesonide is an anti-inflammatory corticosteroid that exhibits
potent glucocorticoid activity and weak mineralocorticoid activity.
The precise mechanism of corticosteroid actions on inflammation in
asthma, Crohn's disease, or ulcerative colitis is not known.
Inflammation is an important component in the pathogenesis of
asthma. Corticosteroids have been shown to have a wide range of
inhibitory activities against multiple cell types (eg, mast cells,
eosinophils, neutrophils, macrophages, and lymphocytes) and
mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines)
involved in allergic and non-allergic-mediated inflammation. These
anti-inflammatory actions of corticosteroids may contribute to
their efficacy in the aforementioned diseases. Because budesonide
undergoes significant first-pass elimination, the both oral
preparations are formulated as an extended release tablet. As a
result, budesonide release is delyaed until exposure to a pH ≥ 7 in
the small intestine.